Description: China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. In addition, it provides Aethoxysklerol for sclerotherapy of different varicose veins; Heling Soothing product for skin soothing; Vmonalisa for mid to deep dermal implantation; Neauvia Hyaluronic Acid series; EyeOP1 to treat glaucoma; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; MOVICOL for treating chronic constipation and faecal impaction; and MeteoSpasmyl to treat gastrointestinal flatulence and pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
Home Page: web.cms.net.cn/zh/home/
Island Place Tower
North Point,
Hong Kong
Phone:
852 2369 7678
Officers
Name | Title |
---|---|
Mr. Kong Lam | Founder, Chairman, CEO & President |
Ms. Yanling Chen | CFO, VP & Executive Director |
Mr. Hongbing Chen | COO, VP, Director of Sales & Marketing and Executive Director |
Ms. Sanyan Wu | Director of Legal Department & Company Secretary |
Dr. Huaizheng Peng M.D., Ph.D. | Chief Business Officer |
Mr. Fei Jiang | Chief Investment Officer of Greater China |
Mr. James Patrick Stearns | Chief Investment Officer of Europe & America |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 8.0841 |
---|---|
Trailing PE: | 13.3571 |
Price-to-Book MRQ: | 1.0911 |
Price-to-Sales TTM: | 0.325 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 5781 |